Manu Chakravarthy
Company: Roche
Job title: SVP and Global Head of Cardiovascular, Renal and Metabolism Product Development
Seminars:
Workshop B: An Understanding of Insulin Resistance, Implications to MASH Pathophysiology 9:00 am
New treatment options are provided by a combination of incretins and insulin sensitizers Insulin sensitizing pharmacology impacts the underlying MASH pathology providing a new understanding of the underlying pathology Incretin treatments impact more than underlying obesity and also provide unique opportunities in combination with insulin sensitizers A round table discussion will discuss which features of…Read more
day: Pre Conf Workshop Day - Clinical & Regulatory Track